Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus cisplatin and pemetrexed for malignant pleural mesothelioma
ACTRN12616001170415Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Dec 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in pleural mesothelioma, sponsored by University of Sydney. Primary endpoint: Progression-free survival at 6 months. Started Dec 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on ACTRN12616001170415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001170415.